Article

Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19

2020-09-15

Abstract excerpt

<h4>ABSTRACT</h4> COVID-19 is a global pandemic that has resulted in over 800,000 deaths. Robust humoral anti-viral immune responses have the potential to generate a diverse set of neutralizing antibodies to eliminate viruses and protect against re-infection, transmission, and the evolution of mutations that escape targeted therapeutics. CD73 is present on the majority of human B cells and a subset of T cells wher...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5ceb7f5e-1f3c-5408-9721-abb2fb63231b
DOI: 10.1101/2020.09.10.20191486

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Characterization and Phase 1 Trial of a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19DOI 10.1101/2020.09.10.20191486Read

Clinical Results with a B Cell Activating Anti-CD73 Antibody for the Immunotherapy of COVID-19Semantic proximity Read

CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancerSemantic proximity Read

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trialSemantic proximity Read

Neutralizing anti-spike monoclonal antibodies for COVID-19 in vulnerable populations: lessons learned and future directions.Semantic proximity Read

Dysregulated inflammation in solid tumor malignancy patients shapes polyfunctional antibody responses to COVID-19 vaccinationSemantic proximity Read

Deep profiling of antigen-specific B cells from different pathogens identifies novel compartments in the IgG memory B cell and antibody-secreting cell lineagesSemantic proximity Read

Immunobridging Analysis of Pemivibart for the Treatment of COVID-19 – A Therapeutic Gap for the Immune Compromised RemainsSemantic proximity Read

Patients with Hematological Malignancies Treated with T-Cell or B-Cell Immunotherapy Remain at High Risk of Severe Forms of COVID-19 in the Omicron EraSemantic proximity Read

First-in-Human Study of a First-in-Class AI-Designed Monoclonal Antibody (GB-0669) Against the Conserved SARS-CoV-2 Spike S2 Stem HelixSemantic proximity Read

SARS-CoV-2 vaccination unmasks distinct immune dysfunctions across lymphoma subtypes and therapiesSemantic proximity Read

The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2Semantic proximity Read

Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19Semantic proximity Read